Amylin, Lilly Partnership Tested By Lilly GLP-1 Project
Executive Summary
Amylin expects to discuss changes to its partnership agreement with Lilly if Lilly's internal GLP-1 antidiabetic compound LY2189265 continues to progress in the clinic
You may also be interested in...
Mystery Suitor Thwarts Bristol’s ImClone Takeover, Or So Icahn Says
Intrigue surrounding Bristol-Myers Squibb's takeover attempt of its Erbitux (cetuximab) marketing partner ImClone reached new heights with the announcement Sept. 10 that a third-party mystery suitor has stepped in with a white knight bid
The Next Bristol/ImClone? “Standstill” Provisions Complicate Other Deals
Roche and Bristol-Myers Squibb have everyone wondering who will be the next company to buy out its biotech partner
Byetta Scripts, LAR Progress Unaffected By Safety Scare, Amylin Says
FDA's review of a new monotherapy indication for Amylin's type 2 diabetes agent Byetta (exenatide) may provide the opportunity for updating the labeling to reflect a stronger warning on pancreatitis